

Abstract

5

- A molecule comprising at least one antigen binding site, comprising in sequence the
hypervariable regions CDR1, CDR2 and CDR3, said CDR1 having the amino acid sequence
Asn-Tyr-Ile-Ile-His (NYIIH), said CDR2 having the amino acid sequence Tyr-Phe-Asn-Pro-
Tyr-Asn-His-Gly-Thr-Lys-Tyr-Asn-Glu-Lys-Phe -Lys-Gly (YFNPYNHGTKYNEKFKG) and
10 said CDR3 having the amino acid sequence Ser-Gly-Pro-Tyr-Ala-Trp-Phe-Asp-Thr
(SGPYAWFDT); e.g. further comprising in sequence the hypervariable regions CDR1',
CDR2' and CDR3', CDR1' having the amino acid sequence Arg-Ala-Ser-Gln-Asn-Ile-Gly-Thr-
Ser-Ile-Gln (RASQNIGTSIQ), CDR2' having the amino acid sequence Ser-Ser-Ser-Glu-Ser-
Ile-Ser (SSSESIS) and CDR3' having the amino acid sequence Gln-Gln-Ser-Asn-Thr-Trp-
15 Pro-Phe-Thr (QQSNTWPFT), e.g. a chimeric or humanised antibody, useful as a
pharmaceutical.